Oncological outcome and recurrence pattern analysis after involved-field irradiation in combination with rituximab for early-stage nodal and extranodal follicular lymphoma

被引：0
|
作者：
Laila König
Klaus Herfarth
Juliane Hörner-Rieber
Sascha Dietrich
Thomas Wiegel
Jürgen Debus
Andreas Viardot
机构：
[1] University Hospital Heidelberg,Department of Radiation Oncology
[2] Heidelberg Institute of Radiation Oncology (HIRO),Department of Internal Medicine V
[3] National Center for Tumor diseases (NCT),Department of Radiation Oncology
[4] University Hospital Heidelberg,Department of Internal Medicine III
[5] University Hospital Ulm,undefined
[6] University Hospital Ulm,undefined
来源：
Strahlentherapie und Onkologie | 2020年 / 196卷
关键词：
Radioimmunotherapy; Immunotherapy; Indolent lymphoma; CD20 antibody; Grade 3A follicular lymphoma;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：705 / 714
页数：9
相关论文
共 50 条
  • [41] INVOLVED-NODE AND INVOLVED-FIELD VOLUMETRIC MODULATED ARC VS. FIXED BEAM INTENSITY-MODULATED RADIOTHERAPY FOR FEMALE PATIENTS WITH EARLY-STAGE SUPRA-DIAPHRAGMATIC HODGKIN LYMPHOMA: A COMPARATIVE PLANNING STUDY
    Weber, Damien C.
    Peguret, Nicolas
    Dipasquale, Glovanna
    Cozzi, Luca
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2009, 75 (05): : 1578 - 1586
  • [42] Involved-Field Radiotherapy (IFRT) after induction chemotherapy with 4-6 cycles of ABVD in early stage (I/IIA) Hodgkin Lymphoma: long term results of a single institution
    Sotiropoulou, A.
    Fragandrea, I.
    Tsalafoutas, I.
    Bakiri, M.
    EJC SUPPLEMENTS, 2009, 7 (02): : 568 - 568
  • [43] Poorer outcome of elderly patients treated with extended-field radiotherapy compared with involved-field radiotherapy after chemotherapy for Hodgkin's lymphoma:: an analysis from the German Hodgkin Study Group
    Klimm, B.
    Eich, H. T.
    Haverkamp, H.
    Lohri, A.
    Koch, P.
    Boissevain, F.
    Trenn, G.
    Worst, P.
    Duehmke, E.
    Mueller, R. P.
    Mueller-Hermelink, K.
    Pfistner, B.
    Diehl, V.
    Engert, A.
    ANNALS OF ONCOLOGY, 2007, 18 (02) : 357 - 363
  • [44] Involved-Field Irradiation in Combination with Total-Body Irradiation (TBI) Does Not Increase Short-Term Toxicity Compared to TBI Alone in Patients with Advanced-Stage Low-Grade Non-Hodgkin Lymphoma
    Marcel Ott
    Heinz Schmidberger
    Bernhard Wörmann
    Clemens F. Albrecht
    Olivier Pradier
    Clemens F. Hess
    Strahlentherapie und Onkologie, 2002, 178 : 245 - 251
  • [45] Involved-field irradiation in combination with total-body irradiation (TBI) does not increase short-term toxicity compared to TBI alone in patients with advanced-stage low-grade non-Hodgkin lymphoma
    Ott, M
    Schmidberger, H
    Wörmann, B
    Albrecht, CF
    Pradier, O
    Hess, CF
    STRAHLENTHERAPIE UND ONKOLOGIE, 2002, 178 (05) : 245 - 251
  • [46] Changes in Treatment Patterns and Overall Survival for Early-Stage Diffuse Large B Cell Lymphoma in the United States After Rituximab: A Population-Based Analysis
    Haque, W.
    Tann, A. W. J.
    Szeja, S.
    Butler, E. B.
    Teh, B. S.
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2016, 96 (02): : S167 - S167
  • [47] Longterm Outcome of Induction Chemotherapy of P-Gemox Regimen Followed By Extensive Involved-Field Radiotherapy(EIFRT) for Newly Diagnosed Stage I/II Extranodal Natural Killer/T-Cell Lymphoma-a Single Center Experience
    Huang, Huiqiang
    Gao, Yan
    Wang, XiaoXiao
    Cai, Qingqing
    Cai, QiChun
    Bai, Bing
    Yan, Zheng
    Jiang, Wenqi
    Xia, Zhongjun
    Li, ZhiMing
    BLOOD, 2015, 126 (23)
  • [48] EARLY STAGE FOLLICULAR LYMPHOMA: BCL2/IGH ANALYSIS AT BASELINE AND FOR MINIMAL RESIDUAL DISEASE MONITORING CAN PREDICT RELAPSE AND DRIVE RITUXIMAB TREATMENT AFTER RADIOTHERAPY
    Cappelli, L. V.
    Pulsoni, A.
    Della Starza, I.
    Cavalli, M.
    De Novi, L. A.
    Tosti, M. E.
    Annechini, G.
    D'Elia, G. M.
    Grapulin, L.
    Guarini, A.
    Del Giudice, I.
    Foa, R.
    HAEMATOLOGICA, 2018, 103 : S59 - S60
  • [49] Rituximab in Combination with CHOP in Patients with Follicular Lymphoma: Analysis of Treatment Outcome of 552 Patients Treated in a Randomized Trial of the German Low Grade Lymphoma Study Group (GLSG) after a Follow up of 58 Months.
    Buske, Christian
    Hoster, Eva
    Dreyling, Martin
    Forstpointner, Roswitha
    Kneba, Michael
    Schmitz, Norbert
    Schmits, Rudolf
    Metzner, Bernd
    Reiser, Marcel
    Lengfelder, Eva
    Woermann, Bernhard J.
    Harder, Harriet
    Hegewisch-Becker, Susanna
    Berdel, Wolfgang E.
    Hess, Georg
    Eimermacher, Hartmut
    Aldaoud, Ali
    Planker, Manfred
    Unterhalt, Michael
    Hiddemann, Wolfgang
    BLOOD, 2008, 112 (11) : 901 - 901
  • [50] Involved-site Radiation Therapy is Equally Effective and Less Toxic Than Involved-field Radiation Therapy in Patients Receiving Combined Modality Treatment for Early-stage Unfavorable Hodgkin Lymphoma-An Analysis of the Randomized Phase 3 HD17 Trial of the German Hodgkin Study Group
    Rosenbrock, Johannes
    Kaul, Helen
    Oertel, Michael
    Celik, Eren
    Linde, Philipp
    Fan, Jiaqi
    Eichenauer, Dennis A.
    Broeckelmann, Paul J.
    von Tresckow, Bastian
    Kobe, Carsten
    Dietlein, Markus
    Fuchs, Michael
    Borchmann, Peter
    Eich, Hans Theodor
    Baues, Christian
    INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2024, 120 (05): : 1344 - 1352
12345